Follow
hazem elkady
hazem elkady
Lecture of Pharmaceutical Medicinal Chemistry and Drug Design Department
Verified email at azhar.edu.eg
Title
Cited by
Cited by
Year
New benzoxazole derivatives as potential VEGFR-2 inhibitors and apoptosis inducers: Design, synthesis, anti-proliferative evaluation, flowcytometric analysis, and in silico studies
H Elkady, A Elwan, HA El-Mahdy, AS Doghish, A Ismail, MS Taghour, ...
Journal of enzyme inhibition and medicinal chemistry 37 (1), 403-416, 2022
1022022
Design, synthesis, and biological evaluation of new challenging thalidomide analogs as potential anticancer immunomodulatory agents
MA El-Zahabi, H Sakr, K El-Adl, M Zayed, AS Abdelraheem, SI Eissa, ...
Bioorganic chemistry 104, 104218, 2020
802020
Discovery of thieno [2, 3-d] pyrimidine-based derivatives as potent VEGFR-2 kinase inhibitors and anti-cancer agents
SA El-Metwally, MM Abou-El-Regal, IH Eissa, ABM Mehany, HA Mahdy, ...
Bioorganic Chemistry 112, 104947, 2021
792021
New quinoxaline derivatives as VEGFR-2 inhibitors with anticancer and apoptotic activity: Design, molecular modeling, and synthesis
NA Alsaif, MA Dahab, MM Alanazi, AJ Obaidullah, AA Al-Mehizia, ...
Bioorganic Chemistry 110, 104807, 2021
742021
Design, synthesis, docking, DFT, MD simulation studies of a new nicotinamide-based derivative: In vitro anticancer and VEGFR-2 inhibitory effects
EB Elkaeed, RG Yousef, H Elkady, IMM Gobaara, BA Alsfouk, DZ Husein, ...
Molecules 27 (14), 4606, 2022
732022
Design and synthesis of thiazolidine-2, 4-diones hybrids with 1, 2-dihydroquinolones and 2-oxindoles as potential VEGFR-2 inhibitors: In-vitro anticancer evaluation and in …
MS Taghour, H Elkady, WM Eldehna, NM El-Deeb, AM Kenawy, ...
Journal of Enzyme Inhibition and Medicinal Chemistry 37 (1), 1903-1917, 2022
702022
Design, synthesis, docking, ADMET studies, and anticancer evaluation of new 3-methylquinoxaline derivatives as VEGFR-2 inhibitors and apoptosis inducers
MM Alanazi, IH Eissa, NA Alsaif, AJ Obaidullah, WA Alanazi, AF Alasmari, ...
Journal of Enzyme Inhibition and Medicinal Chemistry 36 (1), 1760-1782, 2021
692021
New quinoxaline-based VEGFR-2 inhibitors: Design, synthesis, and antiproliferative evaluation with in silico docking, ADMET, toxicity, and DFT studies
MM Alanazi, H Elkady, NA Alsaif, AJ Obaidullah, HM Alkahtani, ...
RSC advances 11 (48), 30315-30328, 2021
522021
Design, synthesis, in silico ADMET profile and GABA‐A docking of novel phthalazines as potent anticonvulsants
AGA El‐Helby, RRA Ayyad, MF Zayed, HS Abulkhair, H Elkady, K El‐Adl
Archiv Der Pharmazie 352 (5), 1800387, 2019
492019
Design and synthesis of new 4-(2-nitrophenoxy) benzamide derivatives as potential antiviral agents: Molecular modeling and in vitro antiviral screening
AE Abdallah, MS Alesawy, SI Eissa, EM El-Fakharany, MH Kalaba, ...
New Journal of Chemistry 45 (36), 16557-16571, 2021
482021
Phthalazine-1, 4-dione derivatives as non-competitive AMPA receptor antagonists: design, synthesis, anticonvulsant evaluation, ADMET profile and molecular docking
AGA El-Helby, RRA Ayyad, K El-Adl, H Elkady
Molecular diversity 23, 283-298, 2019
462019
Discovery of new VEGFR-2 inhibitors based on bis([1, 2, 4]triazolo)[4,3-a:3',4'-c]quinoxaline derivatives as anticancer agents and apoptosis inducers
NA Alsaif, MS Taghour, MM Alanazi, AJ Obaidullah, AA Al-Mehizia, ...
Journal of enzyme inhibition and medicinal chemistry 36 (1), 1093-1114, 2021
442021
Multi-step in silico discovery of natural drugs against COVID-19 targeting main protease
EB Elkaeed, FS Youssef, IH Eissa, H Elkady, AA Alsfouk, ML Ashour, ...
International Journal of Molecular Sciences 23 (13), 6912, 2022
432022
A multistage in silico study of natural potential inhibitors targeting SARS-CoV-2 main protease
EB Elkaeed, IH Eissa, H Elkady, A Abdelalim, AM Alqaisi, AA Alsfouk, ...
International Journal of Molecular Sciences 23 (15), 8407, 2022
382022
Design, synthesis, in vitro biological assessment and molecular modeling insights for novel 3-(naphthalen-1-yl)-4, 5-dihydropyrazoles as anticancer agents with potential EGFR …
WM Eldehna, MA El Hassab, ZM Elsayed, T Al-Warhi, H Elkady, ...
Scientific reports 12 (1), 12821, 2022
382022
The Assessment of Anticancer and VEGFR-2 Inhibitory Activities of a New 1H-Indole Derivative: In Silico and In Vitro Approaches
EB Elkaeed, RG Yousef, H Elkady, IMM Gobaara, AA Alsfouk, DZ Husein, ...
Processes 10 (7), 1391, 2022
382022
Discovery of new quinoxaline-based derivatives as anticancer agents and potent VEGFR-2 inhibitors: Design, synthesis, and in silico study
MM Alanazi, H Elkady, NA Alsaif, AJ Obaidullah, WA Alanazi, ...
Journal of Molecular Structure 1253, 132220, 2022
382022
Design, synthesis and molecular docking of new fused 1H-pyrroles, pyrrolo[3,2-d]pyrimidines and pyrrolo[3,2-e][1, 4]diazepine derivatives as potent EGFR/CDK2 …
A Belal, NM Abdel Gawad, ABM Mehany, MAS Abourehab, H Elkady, ...
Journal of enzyme inhibition and medicinal chemistry 37 (1), 1884-1902, 2022
352022
(E)-N-(3-(1-(2-(4-(2,2,2-Trifluoroacetamido)benzoyl)hydrazono)ethyl)phenyl)nicotinamide: A Novel Pyridine Derivative for Inhibiting Vascular Endothelial Growth …
RG Yousef, H Elkady, EB Elkaeed, IMM Gobaara, HA Al-Ghulikah, ...
Molecules 27 (22), 7719, 2022
332022
Multi-phase in silico discovery of potential SARS-CoV-2 RNA-dependent RNA polymerase inhibitors among 3009 clinical and FDA-approved related drugs
EB Elkaeed, H Elkady, A Belal, BA Alsfouk, TH Ibrahim, M Abdelmoaty, ...
Processes 10 (3), 530, 2022
332022
The system can't perform the operation now. Try again later.
Articles 1–20